Accessibility Menu
Soligenix logo

Soligenix(NASDAQ) SNGX

Market Cap$5.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1991)-100%
5 Year-100%
1 Year-73%
1 Month-5%
$0.37
-1.7%
-0.01Today
Soligenix last closing stock price
MetricPriceDate
Last closeUSD 0.372026-07-24
Soligenix stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.43%USD 0.362026-07-17
1 month-5.04%USD 0.392026-06-24
3 month-73.29%USD 1.392026-04-24
Year to date-72.29%USD 1.342025-12-31
1 year-73.29%USD 1.392025-07-24
3 year-96.3%USD 10.032023-07-25
5 year-99.84%USD 231.272021-07-23
Since inception-100%USD 36,002.301991-05-17

Soligenix Financials at a Glance

Market Cap

$5.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$10.95M

EPS (TTM)

-$1.97

P/E Ratio

-0.19

Dividend

$0.00

Beta (Volatility)

0.60 (Low)

Price

$0.37

Volume

3,999

Open

$0.37

Previous Close

$0.37

Daily Range

$0.36 - $0.37

52-Week Range

$0.28 - $6.23

Estimated Earnings Date

Aug 13, 2026

SNGX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Soligenix

Soligenix develops medicines for rare diseases and public health threats. Its therapies aim to help people with hard-to-treat cancers and immune conditions. The company also works on vaccines for toxins and emerging infections.

What’s in the Soligenix Toolbox?

  • Photodynamic Therapy: HyBryte treats cutaneous T-cell lymphoma, a rare skin cancer; no revenue in 2025.
  • Immune Modulators: SGX942 and SGX945 target inflammation in cancer and rare ulcers; no revenue in 2025.
  • Oral Steroid Formulations: SGX203 and related drugs address severe gut inflammation in children and adults; no revenue in 2025.
  • Vaccine Candidates: RiVax and CiVax aim to prevent ricin poisoning and COVID-19; no revenue in 2025.
  • Thermostable Vaccine Technology: ThermoVax helps vaccines stay effective without refrigeration; no revenue in 2025.

Growth Moves: Soligenix’s Expansion Playbook

  • Launched confirmatory Phase 3 trial for HyBryte in December 2024.
  • Expanded SGX302 into Phase 2a psoriasis trial with new gel in 2025.
  • Completed Phase 2a study for SGX945 in Behçet’s Disease in 2025.
  • Partnered with Sterling Pharma Solutions for drug manufacturing in 2025.
  • Advanced thermostable vaccine and filovirus programs in pre-clinical stages through 2025.

What Makes Soligenix Stand Out?

Soligenix focuses on rare diseases and public health threats, using proprietary drug and vaccine technologies. The company leverages government grants to fund vaccine research, reducing reliance on shareholder capital. Its small team and targeted pipeline allow for nimble operations in a high-risk sector.

Five Things You Need to Know

  • Revenue was $0 in 2025, down 100% from 2024.
  • Net loss was $11.08 million in 2025, up 34% from 2024.
  • Research and development expenses rose 43% to $7.49 million in 2025.
  • Cash and cash equivalents were $7.94 million as of December 31, 2025.
  • No debt outstanding as of December 31, 2025; all funding from equity and grants.

Bottom Line

Soligenix remains a research-driven biotech with no commercial products and ongoing losses. Its future depends on clinical trial success and new funding sources.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

14

CEO

Christopher J. Schaber, PhD

Website

www.soligenix.com

Headquarters

Princeton, NJ 08540, US

SNGX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-246.04%

Return on Capital

-209.64%

Return on Assets

-158.24%

Earnings Yield

-5.26%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

14.82M

Volume

4.00K

Avg. Volume

7.59M

Financials (TTM)

Gross Profit

-$2.10K

Operating Income

-$11.70M

EBITDA

-$11.46M

Operating Cash Flow

-$10.78M

Capital Expenditure

$3.00

Free Cash Flow

-$10.78M

Cash & ST Invst.

$6.03M

Total Debt

$330.66K

Soligenix Performance Analysis

Soligenix annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 250,000649.6%
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Soligenix sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Soligenix annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -76.892.4%
20232023-12-31USD -12.66-83.5%
20242024-12-31USD -4.98-60.7%
20252025-12-31USD -2.14-57.1%
Soligenix sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3022.6%
Q32025-09-3029.3%
Q42025-12-3150.0%
Q12026-03-313.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$1.10K

N/A

Gross Margin

0.00%

N/A

Market Cap

$5.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$393.16K

N/A

Employees

14

N/A

Net Income

-$2.82M

+12.7%

EBITDA

-$2.82M

+12.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$6.03M

-17.4%

Total Debt

$330.66K

+317.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$213.43K

N/A

Short Term Debt

$117.24K

+48.2%

Return on Assets

-1.58%

N/A

Return on Invested Capital

-3.54%

N/A

Free Cash Flow

-$2.36M

-27.7%

Operating Cash Flow

-$2.36M

-27.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
QLGNQualigen Therapeutics, Inc.
$3.21+5.59%
SILOSilo Pharma, Inc.
$4.40-1.57%
XBIOXenetic Biosciences, Inc.
$2.50-5.30%
TTNPTitan Pharmaceuticals, Inc.
$2.34-11.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.67-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%

Questions About SNGX

What is the current price of Soligenix?

Soligenix is trading at $0.37 per share.

What is the 52-week range for Soligenix?

Over the past 52 weeks, Soligenix has traded between $0.28 and $6.23.

How much debt does Soligenix have?

As of the most recent reporting period, Soligenix reported total debt of $330.66K.

How much cash does Soligenix have on hand?

Soligenix reported $6.03M in cash and cash equivalents in its most recent financial results.

What is Soligenix’s dividend yield?

Soligenix does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services